Thursday, 21 October 2021

 

 

LATEST NEWS Make All Efforts For Instilling Confidence Of General Public In Law And Order Machinery- Cm To Punjab Police Youth To Be Deciding Factor In Vidhan Sabha Polls : Charanjit Singh Channi Massive protest against Cong MLA Joginderpal at Pathankot Police Commemoration Day observed at DPL Pulwama Intense Dengue control measures afoot Punjab Government To Come Up With A Roadmap To Revamp Education System : Pargat Singh The public knows who did corruption and who went to the court for the same : Vinod Thakur Central University of Punjab organized an Invited lecture on “Universal Human Values” Raja Warring's report card does not include any action against political transport mafia : Dinesh Chadha Tamannah Bhatia among top 10 most influential social media stars in south Being Punjabi an advantage in portraying a 'Sardar' : Pawan Malhotra Debina Bonnerjee's prosthetics for 'Shubho Bijoya' will leave you in shock Government recognizes Purzgars as vital pillar in Shawl Industry Police Martyrs Day observed at DPL Ganderbal, Pulwama Director Agriculture Kashmir inaugurates sale of Vegetable seedlings at Kitchen Garden, Lal Mandi Snow forecast : DC Bandipora reviews winter preparedness Disst. Adm. Kupwara organizes 4 block diwas programmes at Hayhama, Langate, Kalaroos, Tad Sonamarg to be promoted as all season tourist destination : Pandurang Kondbara Pole Charanjit Singh Channi Reviews Preparedness For Progressive Punjab Investors Summit We Should Fight Anti-National Forces Jointly : Gurpreet Singh Bhullar Commissionerate Police Give Rousing Welcome To Motorcycle Rally On Its Arrival At Jalandhar To Mark National Unity Day

 

Hyderabad's Yashoda Hospitals to conduct Phase 3 trial of Molnupiravir

Coronavirus, COVID 19, Fight Against Corona, Covaxin, Covishield, Covid-19 Vaccine, Oxygen, Oxygen Cylinders, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen supply, Liquid Medical Oxygen, Drug Controller General of India, DCGI, Yashoda Hospitals Hyderabad, NatcoPharma, Somajigida, Molnupiravir

Web Admin

Web Admin

5 Dariya News

Hyderabad , 21 May 2021

Hyderabad's Yashoda Hospitals will start Phase 3 trials of Molnupiravir, in association with NatcoPharma, in their Somajigida unit, the private hospital announced on Friday.NatcoPharma has already received approval from Drug Controller General of India (DCGI) for conducting clinical trials for oral administration of Molnupiravir capsules for patients with mild and moderate Covid-19 symptoms.The clinical trials at Yashoda Hospitals will entail the Covid patient volunteers to take 800 mg twice a day without being admitted in the hospital, since it is a OPD (out-patient department) based clinical trial. The patient volunteers regular interactions with their physicians on day 5, day 10 and day 15 for their follow up cycle at the hospital.Announcing the commencement of the trials, Dr Lingaiah Amidalya, Medical Director of Yashoda Hospitals, said it was a privilege to be the first hospital in India chosen for the Phase 3 of the clinical trials."We hope that the trial is a success proving it to be a game changer. If patients can be treated with Molnupiravir in the mild stage of the disease, the transmission of Covid-19 can be controlled and further worsening of the disease can be prevented at large scale. 

Thus, the disease burden on the healthcare system as well as the society could well be reduced, with significant implications on the financial burden of the common man and their out of pocket expense."Molnupiravir is a prodrug of the active antiviral ribonucleoside analogue of a-d-N4-hydroxycytidine. Its activity against SARS-CoV-2 is by inhibition of RNA-dependent-RNA polymerase. Molnupiravir leads to errors in the viral RNA sequence, stopping viral replication, shortening infection, and limiting disease transmission.Scientists at Emory University USA have anticipated the capsule to take effect within 24 hours of the dose and that the oral administration of the capsule on Covid severe patients will help reduce the severity of the symptoms.Pre-clinical (animal) studies have found that Molnupiravir has remarkably reduced SARS-CoV-2 load and was found to have completely suppressed the spread of disease from animal to animal, and the virus multiplication development had stopped.In a Phase 1 clinical trial conducted in the UK, Molnupiravir was deemed to be safe and well tolerated up to 800 mg twice a day for 5 days in healthy trial subjects.In the Phase 2 clinical trials conducted in the US, all patients who received Molnupiravir for 5 days were found to have a negative SARS-CoV-2 culture after the 5-day treatment duration.

 

Tags: Coronavirus , COVID 19 , Fight Against Corona , Covaxin , Covishield , Covid-19 Vaccine , Oxygen , Oxygen Cylinders , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen supply , Liquid Medical Oxygen , Drug Controller General of India , DCGI , Yashoda Hospitals Hyderabad , NatcoPharma , Somajigida , Molnupiravir

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2021 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD